Skip to main content

Advertisement

Table 3 Correlation of MAPK immunoreactivity and mutational status of KRAS in low- and high-grade OSCs

From: P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas

  Low-grade High-grade
(No. of cases) (No. of cases)
KRAS mutation   
MAPK + 5 1
MAPK – 1 7
Wild KRAS   
MAPK + 2 11
MAPK – 3 43
Total cases 11 62